Welcome to our dedicated page for United Health Pr SEC filings (Ticker: UEEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Health Products filings document the public reporting, financing and governance record of an operating medical-products company focused on hemostatic gauze. The company's regulatory disclosures include annual reporting status, registration statement materials, material-event reports and capital-structure information related to common stock, warrants, restricted stock units and private placements.
Recent filing themes include late annual report notifications, S-1 registration disclosures, and 8-K reports for material definitive agreements such as securities purchase agreements, registration rights arrangements and convertible promissory notes. The filings also address business risks, liquidity, equity compensation and regulatory matters connected to the company's hemostatic gauze products.
United Health Products, Inc. files a prospectus supplement to register 25,669,288 shares of common stock for resale by a selling security holder under its effective Form S-1. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The supplement notes the Company’s OTCQB last quoted price of $0.054 per share as of May 21, 2026, and states shares issued and outstanding were 260,385,588 as of May 15, 2026. The 10-Q discloses a going concern warning, negative working capital, deferred offering costs of $169,582, and derivative liabilities of $118,844 as of March 31, 2026.
United Health Products, Inc. reported another pre-revenue quarter, posting a Q1 2026 net loss of $315,842, a sharp improvement from $1,531,659 a year earlier mainly due to much lower stock-based compensation and reduced R&D and consulting spend.
The company ended the quarter with only $1,029 in cash, a working capital deficit of $4,143,918, total assets of $248,825 and stockholders’ deficit of $4,192,293, and auditors highlight substantial doubt about its ability to continue as a going concern.
UHP remains focused on securing FDA Class III Premarket Approval for its CelluSTAT hemostatic gauze, but is operating under an FDA Warning Letter related to its 2018–2019 clinical study, must complete a GCP audit by late July 2026, and may rely on a prospective corporate partner to serve as sponsor of a new pivotal IDE study. To fund operations it is using highly dilutive instruments including convertible notes and an Any Market Purchase Agreement with Alumni Capital of up to $4,000,000, alongside 40.3 million unvested RSUs and 3.9 million warrants outstanding.
United Health Products, Inc. registers 25,669,288 shares of common stock for resale by Alumni Capital LP pursuant to agreements the company entered into on December 16, 2025. The registered shares comprise (i) 15,000,000 shares issuable under an Any Market Purchase Agreement (AMPA), (ii) 3,484,321 shares issuable upon exercise of a five‑year Commitment Warrant at $0.07462 per share, and (iii) 7,184,967 shares issuable upon conversion of a senior convertible note with an initial conversion price of $0.06039 per share. Alumni may sell the shares on the OTCQB (ticker UEEC) or otherwise; the company will not receive proceeds from Alumni’s resale activity, although it may receive proceeds if it elects to sell shares to Alumni under the AMPA or if the Commitment Warrant is exercised for cash. The prospectus discloses that the company had 258,690,253 shares outstanding prior to this offering and presents an assumed post‑issuance figure of 284,359,541 shares if all referenced issuances occur.
United Health Products, Inc. files a post-effective amendment to its Form S-1 registering 25,669,288 shares of common stock for resale by Alumni Capital LP. The registration includes (i) up to 15,000,000 shares the company may sell to Alumni under an Any Market Purchase Agreement, (ii) 3,484,321 shares issuable on a Commitment Warrant, and (iii) 7,184,967 shares issuable upon conversion of a $289,267 senior convertible note.
The amendment updates the S-1 to incorporate the company’s Form 10-K for the year ended December 31, 2025. The selling security holder will receive proceeds from any resale; the company may receive proceeds only from shares it elects to sell under the AMPA and from cash exercises of the Commitment Warrant. The prospectus discloses material FDA interactions on its Class III PMA pathway, identified internal-control weaknesses, a going-concern audit qualification, and working capital constraints.
United Health Products, Inc. reports another development-stage year focused on its CelluSTAT hemostatic gauze, with no revenue and a net loss of $2,669,348 for 2025, compared with a $2,001,733 loss in 2024. Operating expenses rose to $2,255,474, driven largely by higher stock-based compensation.
The company is seeking FDA Premarket Approval for Class III surgical use of CelluSTAT and is responding to an FDA Warning Letter tied to its 2018–2019 clinical study, including corrective actions and an external GCP audit. As of December 31, 2025, it had cash of $65,249, a working capital deficit of $3,837,757, and its auditor expressed substantial doubt about its ability to continue as a going concern.
To fund operations, UHP relied on equity-linked financing, including a $289,267 senior convertible note from Alumni Capital with $250,000 proceeds and an Any Market Purchase Agreement allowing sales of up to $4,000,000 of common stock through 2027. Management continues to explore strategic options such as partnerships, licensing, or a sale while pausing most commercial activity to focus on regulatory approvals.
United Health Products, Inc. notified the SEC that it could not file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 on time due to an extended auditors' final review caused by delayed debt confirmation responses from certain investors; the company expects to file within the fifteen-calendar day extension period.
The company reports total operating expenses of $2,438,765 for 2025 versus $2,007,572 in 2024, driven largely by a $1,270,772 increase in stock-based compensation (including vesting of 4,725,000 RSUs recorded as $1,120,125) and cites other income (expense) of $(442,342) for 2025 versus $5,839 in 2024. Net loss was $2,881,107 for 2025 versus $2,001,733 for 2024.
United Health Products, Inc. is registering up to 25,669,288 shares of common stock for resale by Alumni Capital LP. This total includes 15,000,000 shares that may be sold to Alumni under a $4,000,000 Any Market Purchase Agreement, 3,484,321 shares issuable on exercise of a warrant at $0.07462, and 7,184,967 shares issuable on conversion of a $289,267 senior convertible note at $0.06039 per share. Common shares outstanding were 258,690,253 as of January 14, 2026, and would be 284,359,541 if all these shares are issued. The company will not receive proceeds from Alumni’s resales but may receive cash from future share sales to Alumni and any cash warrant exercises.
United Health Products develops the CelluSTAT hemostatic gauze and is seeking FDA Premarket Approval to enter the Class III human surgical market. A 2019 trial showed faster time to hemostasis versus a leading competitor, but the FDA has issued a Warning Letter citing five clinical procedure violations, and resolution timing is uncertain. The company reports recurring losses, a going concern warning from its auditors, needs additional financing to fund its plan, and faces significant regulatory, dilution, liquidity and “penny stock” risks.
United Health Products, Inc. entered into new financing arrangements with Alumni Capital LP, including a senior convertible promissory note and an equity purchase facility. The note has a principal amount of $289,821, bears interest at 15% per annum, provided $250,000 of net proceeds at closing, and is due on or before December 31, 2026, with conversion into common stock allowed at $0.06 per share, subject to adjustments and a 9.99% ownership cap. The company agreed to reserve up to the lower of 20,000,000 shares or 150% of the maximum number of conversion shares and to file a resale registration statement on Form S-1 for the note shares by January 15, 2026.
The company also put in place an Any Market Purchase Agreement giving it the right to sell up to $4,000,000 of common stock to Alumni through December 31, 2027 or until the full commitment is purchased, with individual drawdowns generally based on 90% of the two lowest five-day VWAPs. In connection with this facility, Alumni received a five-year warrant to purchase up to 3,484,321 shares at $0.075 per share. Both the note and share issuances rely on private-offering exemptions and are supported by registration rights for future resales.
United Health Products (UEEC) filed its Q3 2025 report, showing no revenue as the company focuses on FDA approval for its CelluSTAT surgical hemostatic gauze. The quarter recorded a net loss of $285,594, and the nine-month period showed a net loss of $2,132,440.
Liquidity remains tight: cash stood at $18,376 and working capital was negative $1,963,227. Management stated there is substantial doubt about the company’s ability to continue as a going concern. Financing activity included $420,000 in new convertible notes during the nine months and 800,000 shares sold under the White Lion facility for $63,308; the CSPA commitment period ended on October 1, 2025. Shares outstanding were 258,690,253 as of November 14, 2025.
Regulatory progress remains the key driver. The FDA issued a Warning Letter related to the 2019 clinical study, and in April 2025 the FDA disapproved UHP’s IDE for a 27‑subject supplemental trial pending resolution of that letter. Subsequent to quarter end, UHP received $100,000 via a 60‑day promissory note at 13%, convertible at the holder’s election into notes maturing December 31, 2026.